Synarc Acquires IoDP

Synarc, Inc. (Maynard, MA, USA), a provider of highly specialized medical imaging and molecular marker services for global clinical trials, has completed the acquisition of IoDP Medical Imaging Research (Paris, France), a provider of medical imaging services focused on clinical trials in cardiovascular disease, stroke, and other indications concentrated on contrast media studies, asthma, and retinal angiography analysis. Their technology also includes left ventricle mass measurement, as well as rate of contrast enhancement of the left ventricle in magnetic resonance imaging (MRI) systems, for lung computed tomography (CT) analysis in asthma, and retinal angiography analysis.

IoDP has performed a considerable number of multinational and multicenter trials. The company's technology allows precise and reproducible measurements of the thickness of the intima of the carotid artery in atherosclerosis trials.

"The synergy between Synarc's strong presence in medical imaging and IoDP's knowledge base and experience in cardiovascular and neurovascular disease make this an important strategic acquisition for us, remarked Peter Steiger, Ph.D., Synarc's CEO and President.




Related Links:
Synarc